RecallRadar

FDA Drug recall D-0650-2021

Xolair (omalizumab) Injection, 150 mg/1 mL, 1 prefilled syringe, Rx Only, For Subcutaneous Use

On 2021-07-14 the FDA classified a Class II recall of Xolair (omalizumab) Injection, 150 mg/1 mL, 1 prefilled syringe, Rx Only, For Subcutaneous Use by Genentech, citing failed Stability Specifications: Out of Specification results of Polysorbate 20 (PS20) content were detected at the 12 month testing time point.

Read the official FDA Drug notice

AgencyFDA Drug
Recall numberD-0650-2021
ClassificationClass II
Statusterminated
Initiated2021-06-09
Published2021-07-14
Last updated2026-09-13 11:52 UTC
CompanyGenentech
DistributionUS

Product

Xolair (omalizumab) Injection, 150 mg/1 mL, 1 prefilled syringe, Rx Only, For Subcutaneous Use. Single-Dose Prefilled Syringe. Product of France, Manufactured by: Genentech, Inc. A Member of the Roche Group, South San Francisco, CA 9480-4990. NDC: 50242-215-01

Reason

Failed Stability Specifications: Out of Specification results of Polysorbate 20 (PS20) content were detected at the 12 month testing time point.

Identifiers

ndc50242-040-62
ndc50242-040-86
ndc50242-214-01
ndc50242-214-86
ndc50242-214-03
ndc50242-214-55
ndc50242-214-99
ndc50242-214-83
ndc50242-215-86
ndc50242-215-01
ndc50242-215-03
ndc50242-215-55
ndc50242-215-99
ndc50242-215-83
ndc50242-227-01
ndc50242-227-55
ndc50242-227-99
ndc50242-227-86
code_infoLot No.: 3352758, Exp. Date Aug 2021; Lot No.: 3352759, Exp. Date Aug 2021

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.

Source

Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0650-2021%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.